{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:15:03Z","timestamp":1793898903011,"version":"4.8.0"},"reference-count":174,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Immunol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41590-026-02616-1","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T09:01:40Z","timestamp":1787302900000},"page":"1804-1814","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Collaborative functionality between three types of inflammation in idiopathic pulmonary fibrosis"],"prefix":"10.1038","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4394-4533","authenticated-orcid":false,"given":"Thomas","family":"Fabre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Wynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5406-5473","authenticated-orcid":false,"given":"Kevin M.","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"2616_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-03481-8","volume":"11","author":"M Gagliardi","year":"2021","unstructured":"Gagliardi, M. et al. Real-life prevalence of progressive fibrosing interstitial lung diseases. Sci. Rep. 11, 23988 (2021).","journal-title":"Sci. Rep."},{"key":"2616_CR2","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1183\/09059180.00002512","volume":"21","author":"L Nalysnyk","year":"2012","unstructured":"Nalysnyk, L., Cid-Ruzafa, J., Rotella, P. & Esser, D. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur. Respir. Rev. 21, 355\u2013361 (2012).","journal-title":"Eur. Respir. Rev."},{"key":"2616_CR3","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1183\/09031936.00185114","volume":"46","author":"J Hutchinson","year":"2015","unstructured":"Hutchinson, J., Fogarty, A., Hubbard, R. & McKeever, T. Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur. Respir. J. 46, 795\u2013806 (2015).","journal-title":"Eur. Respir. J."},{"key":"2616_CR4","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12931-021-01791-z","volume":"22","author":"TM Maher","year":"2021","unstructured":"Maher, T. M. et al. Global incidence and prevalence of idiopathic pulmonary fibrosis. Respir. Res. 22, 197 (2021).","journal-title":"Respir. Res."},{"key":"2616_CR5","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1164\/rccm.201006-0894CI","volume":"183","author":"B Ley","year":"2011","unstructured":"Ley, B., Collard, H. R. & King, T. E. Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 183, 431\u2013440 (2011).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2616_CR6","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1159\/000504630","volume":"99","author":"KM Mortimer","year":"2020","unstructured":"Mortimer, K. M. et al. Characterizing health outcomes in idiopathic pulmonary fibrosis using US health claims data. Respiration 99, 108\u2013118 (2020).","journal-title":"Respiration"},{"key":"2616_CR7","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1001\/jama.2024.3669","volume":"331","author":"TM Maher","year":"2024","unstructured":"Maher, T. M. Interstitial lung disease: a review. JAMA 331, 1655\u20131665 (2024).","journal-title":"JAMA"},{"key":"2616_CR8","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.2147\/JIR.S280958","volume":"13","author":"JE Michalski","year":"2020","unstructured":"Michalski, J. E. & Schwartz, D. A. Genetic risk factors for idiopathic pulmonary fibrosis: insights into immunopathogenesis. J. Inflamm. Res. 13, 1305\u20131318 (2020).","journal-title":"J. Inflamm. Res."},{"key":"2616_CR9","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1172\/JCI60323","volume":"122","author":"PW Noble","year":"2012","unstructured":"Noble, P. W., Barkauskas, C. E. & Jiang, D. Pulmonary fibrosis: patterns and perpetrators. J. Clin. Invest. 122, 2756\u20132762 (2012).","journal-title":"J. Clin. Invest."},{"key":"2616_CR10","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1183\/09059180.00001514","volume":"23","author":"A Devaraj","year":"2014","unstructured":"Devaraj, A. Imaging: how to recognise idiopathic pulmonary fibrosis. Eur. Respir. Rev. 23, 215\u2013219 (2014).","journal-title":"Eur. Respir. Rev."},{"key":"2616_CR11","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1055\/s-0042-1755563","volume":"43","author":"K Rodriguez","year":"2022","unstructured":"Rodriguez, K., Ashby, C. L., Varela, V. R. & Sharma, A. High-resolution computed tomography of fibrotic interstitial lung disease. Semin. Respir. Crit. Care Med. 43, 764\u2013779 (2022).","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"2616_CR12","doi-asserted-by":"publisher","first-page":"133","DOI":"10.23736\/S2724-5691.23.09948-3","volume":"79","author":"P Lyberis","year":"2024","unstructured":"Lyberis, P. et al. Correlation between high-resolution computed tomography appearance and histopathological features in the diagnosis of interstitial lung diseases. A real-life study. Minerva Surg. 79, 133\u2013139 (2024).","journal-title":"Minerva Surg."},{"key":"2616_CR13","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1164\/rccm.200412-1756OC","volume":"172","author":"DA Lynch","year":"2005","unstructured":"Lynch, D. A. et al. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am. J. Respir. Crit. Care Med. 172, 488\u2013493 (2005).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2616_CR14","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1378\/chest.110.2.378","volume":"110","author":"TE Hartman","year":"1996","unstructured":"Hartman, T. E. et al. Disease progression in usual interstitial pneumonia compared with desquamative interstitial pneumonia. Assessment with serial CT. Chest 110, 378\u2013382 (1996).","journal-title":"Chest"},{"key":"2616_CR15","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/00005382-199807000-00007","volume":"13","author":"JS Lee","year":"1998","unstructured":"Lee, J. S., Gong, G., Song, K. S., Kim, D. S. & Lim, T. H. Usual interstitial pneumonia: relationship between disease activity and the progression of honeycombing at thin-section computed tomography. J. Thorac. Imaging 13, 199\u2013203 (1998).","journal-title":"J. Thorac. Imaging"},{"key":"2616_CR16","doi-asserted-by":"publisher","unstructured":"Parimon, T., Yao, C., Stripp, B. R., Noble, P. W. & Chen, P. Alveolar epithelial type II cells as drivers of lung fibrosis in idiopathic pulmonary fibrosis. Int. J. Mol. Sci. 21, 2269 https:\/\/doi.org\/10.3390\/ijms21072269 (2020).","DOI":"10.3390\/ijms21072269"},{"key":"2616_CR17","doi-asserted-by":"publisher","first-page":"10562","DOI":"10.1073\/pnas.1107559108","volume":"108","author":"WE Lawson","year":"2011","unstructured":"Lawson, W. E. et al. Endoplasmic reticulum stress enhances fibrotic remodeling in the lungs. Proc. Natl Acad. Sci. USA 108, 10562\u201310567 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2616_CR18","first-page":"L1192","volume":"275","author":"BD Uhal","year":"1998","unstructured":"Uhal, B. D. et al. Alveolar epithelial cell death adjacent to underlying myofibroblasts in advanced fibrotic human lung. Am. J. Physiol. 275, L1192\u2013L1199 (1998).","journal-title":"Am. J. Physiol."},{"key":"2616_CR19","doi-asserted-by":"publisher","unstructured":"Shenderov, K., Collins, S. L., Powell, J. D. & Horton, M. R. Immune dysregulation as a driver of idiopathic pulmonary fibrosis. J. Clin. Invest. 131, e143226 https:\/\/doi.org\/10.1172\/JCI143226 (2021).","DOI":"10.1172\/JCI143226"},{"key":"2616_CR20","doi-asserted-by":"publisher","first-page":"C2","DOI":"10.1152\/ajpcell.00097.2023","volume":"325","author":"E Fliesser","year":"2023","unstructured":"Fliesser, E., Lins, T., Berg, J. L., Kolb, M. & Kwapiszewska, G. The endothelium in lung fibrosis: a core signaling hub in disease pathogenesis? Am. J. Physiol. Cell Physiol. 325, C2\u2013C16 (2023).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"2616_CR21","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/s41588-025-02080-x","volume":"57","author":"A Vannan","year":"2025","unstructured":"Vannan, A. et al. Spatial transcriptomics identifies molecular niche dysregulation associated with distal lung remodeling in pulmonary fibrosis. Nat. Genet. 57, 647\u2013658 (2025).","journal-title":"Nat. Genet."},{"key":"2616_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41621-y","volume":"14","author":"RJ Hewitt","year":"2023","unstructured":"Hewitt, R. J. et al. Lung extracellular matrix modulates KRT5+ basal cell activity in pulmonary fibrosis. Nat. Commun. 14, 6039 (2023).","journal-title":"Nat. Commun."},{"key":"2616_CR23","doi-asserted-by":"publisher","unstructured":"Hirano, T. et al. Keratin-5-positive basal-like epithelial cells associate with forced vital capacity in idiopathic pulmonary fibrosis; a cross-sectional analysis. ERJ Open Res. 12, 00742-2025 https:\/\/doi.org\/10.1183\/23120541.00742-2025 (2026).","DOI":"10.1183\/23120541.00742-2025"},{"key":"2616_CR24","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1146\/annurev-pathol-042320-030240","volume":"17","author":"BJ Moss","year":"2022","unstructured":"Moss, B. J., Ryter, S. W. & Rosas, I. O. Pathogenic mechanisms underlying idiopathic pulmonary fibrosis. Annu. Rev. Pathol. 17, 515\u2013546 (2022).","journal-title":"Annu. Rev. Pathol."},{"key":"2616_CR25","doi-asserted-by":"publisher","unstructured":"Chakraborty, A., Mastalerz, M., Ansari, M., Schiller, H. B. & Staab-Weijnitz, C. A. Emerging roles of airway epithelial cells in idiopathic pulmonary fibrosis. Cells 11, 1050 https:\/\/doi.org\/10.3390\/cells11061050 (2022).","DOI":"10.3390\/cells11061050"},{"key":"2616_CR26","doi-asserted-by":"publisher","unstructured":"Bell, P. T. & Belz, G. T. Fibroblasts as regulators of lung immunity, repair and fibrosis. Nat. Rev. Immunol. 26, 455\u2013471 https:\/\/doi.org\/10.1038\/s41577-026-01268-4 (2026).","DOI":"10.1038\/s41577-026-01268-4"},{"key":"2616_CR27","doi-asserted-by":"publisher","first-page":"C1964","DOI":"10.1152\/ajpcell.00285.2025","volume":"328","author":"T Tsukui","year":"2025","unstructured":"Tsukui, T. & Sheppard, D. Stromal heterogeneity in the adult lung delineated by single-cell genomics. Am. J. Physiol. Cell Physiol. 328, C1964\u2013C1972 (2025).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"2616_CR28","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1165\/rcmb.2012-0335OC","volume":"48","author":"A Marinkovic","year":"2013","unstructured":"Marinkovic, A., Liu, F. & Tschumperlin, D. J. Matrices of physiologic stiffness potently inactivate idiopathic pulmonary fibrosis fibroblasts. Am. J. Respir. Cell Mol. Biol. 48, 422\u2013430 (2013).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"2616_CR29","doi-asserted-by":"publisher","unstructured":"Mondoni, M. et al. Vascular involvement in idiopathic pulmonary fibrosis. ERJ Open Res. 10, 00550-2024 https:\/\/doi.org\/10.1183\/23120541.00550-2024 (2024).","DOI":"10.1183\/23120541.00550-2024"},{"key":"2616_CR30","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1136\/thoraxjnl-2019-214375","volume":"76","author":"ND Weatherley","year":"2021","unstructured":"Weatherley, N. D. et al. Quantification of pulmonary perfusion in idiopathic pulmonary fibrosis with first pass dynamic contrast-enhanced perfusion MRI. Thorax 76, 144\u2013151 (2021).","journal-title":"Thorax"},{"key":"2616_CR31","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1126\/science.aam6603","volume":"359","author":"AN Nabhan","year":"2018","unstructured":"Nabhan, A. N., Brownfield, D. G., Harbury, P. B., Krasnow, M. A. & Desai, T. J. Single-cell Wnt signaling niches maintain stemness of alveolar type 2 cells. Science 359, 1118\u20131123 (2018).","journal-title":"Science"},{"key":"2616_CR32","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/s41586-024-07660-1","volume":"631","author":"T Tsukui","year":"2024","unstructured":"Tsukui, T., Wolters, P. J. & Sheppard, D. Alveolar fibroblast lineage orchestrates lung inflammation and fibrosis. Nature 631, 627\u2013634 (2024).","journal-title":"Nature"},{"key":"2616_CR33","doi-asserted-by":"publisher","DOI":"10.1111\/acel.14503","volume":"24","author":"A Lingampally","year":"2025","unstructured":"Lingampally, A. et al. Unraveling alveolar fibroblast and activated myofibroblast heterogeneity and differentiation trajectories during lung fibrosis development and resolution in young and old mice. Aging Cell 24, e14503 (2025).","journal-title":"Aging Cell"},{"key":"2616_CR34","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.immuni.2019.02.002","volume":"50","author":"MW Dahlgren","year":"2019","unstructured":"Dahlgren, M. W. et al. Adventitial stromal cells define group 2 innate lymphoid cell tissue niches. Immunity 50, 707\u2013722 (2019).","journal-title":"Immunity"},{"key":"2616_CR35","doi-asserted-by":"publisher","unstructured":"Narvaez Del Pilar, O., Gacha Garay, M. J. & Chen, J. Three-axis classification of mouse lung mesenchymal cells reveals two populations of myofibroblasts. Development 149, dev200081 https:\/\/doi.org\/10.1242\/dev.200081 (2022).","DOI":"10.1242\/dev.200081"},{"key":"2616_CR36","doi-asserted-by":"publisher","unstructured":"Cowan, M. J. B., Davidson, S., Coles, M. & Buckley, C. D. The role of fibroblasts across inflammation and immunity. Annu. Rev. Pathol. 21, 423\u2013445 https:\/\/doi.org\/10.1146\/annurev-pathmechdis-080624-105114 (2025).","DOI":"10.1146\/annurev-pathmechdis-080624-105114"},{"key":"2616_CR37","doi-asserted-by":"publisher","unstructured":"Wei, K., Nguyen, H. N. & Brenner, M. B. Fibroblast pathology in inflammatory diseases. J. Clin. Invest. 131, e149538 https:\/\/doi.org\/10.1172\/JCI149538 (2021).","DOI":"10.1172\/JCI149538"},{"key":"2616_CR38","doi-asserted-by":"publisher","unstructured":"Molina, C. et al. Clonal expansion of alveolar fibroblast progeny drives pulmonary fibrosis in mouse models. J. Clin. Invest. 135, e191826 https:\/\/doi.org\/10.1172\/JCI191826 (2025).","DOI":"10.1172\/JCI191826"},{"key":"2616_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15647-5","volume":"11","author":"T Tsukui","year":"2020","unstructured":"Tsukui, T. et al. Collagen-producing lung cell atlas identifies multiple subsets with distinct localization and relevance to fibrosis. Nat. Commun. 11, 1920 (2020).","journal-title":"Nat. Commun."},{"key":"2616_CR40","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.add8945","volume":"8","author":"T Fabre","year":"2023","unstructured":"Fabre, T. et al. Identification of a broadly fibrogenic macrophage subset induced by type 3 inflammation. Sci. Immunol. 8, eadd8945 (2023).","journal-title":"Sci. Immunol."},{"key":"2616_CR41","doi-asserted-by":"publisher","unstructured":"Morse, C. et al. Proliferating SPP1\/MERTK-expressing macrophages in idiopathic pulmonary fibrosis. Eur. Respir. J. 54, 1802441 https:\/\/doi.org\/10.1183\/13993003.02441-2018 (2019).","DOI":"10.1183\/13993003.02441-2018"},{"key":"2616_CR42","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1038\/s41591-023-02327-2","volume":"29","author":"L Sikkema","year":"2023","unstructured":"Sikkema, L. et al. An integrated cell atlas of the lung in health and disease. Nat. Med. 29, 1563\u20131577 (2023).","journal-title":"Nat. Med."},{"key":"2616_CR43","doi-asserted-by":"publisher","unstructured":"Lingampally, A. et al. Evidence for a lipofibroblast-to-Cthrc1+ myofibroblast reversible switch during the development and resolution of lung fibrosis in young mice. Eur. Respir. J. 65, 2300482 https:\/\/doi.org\/10.1183\/13993003.00482-2023 (2025).","DOI":"10.1183\/13993003.00482-2023"},{"key":"2616_CR44","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/s41586-021-03549-5","volume":"593","author":"MB Buechler","year":"2021","unstructured":"Buechler, M. B. et al. Cross-tissue organization of the fibroblast lineage. Nature 593, 575\u2013579 (2021).","journal-title":"Nature"},{"key":"2616_CR45","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/s41586-025-08727-3","volume":"641","author":"JL Guo","year":"2025","unstructured":"Guo, J. L. et al. Histological signatures map anti-fibrotic factors in mouse and human lungs. Nature 641, 993\u20131004 (2025).","journal-title":"Nature"},{"key":"2616_CR46","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41586-024-08542-2","volume":"640","author":"Y Fang","year":"2025","unstructured":"Fang, Y. et al. RUNX2 promotes fibrosis via an alveolar-to-pathological fibroblast transition. Nature 640, 221\u2013230 (2025).","journal-title":"Nature"},{"key":"2616_CR47","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.immuni.2016.02.024","volume":"44","author":"F Ginhoux","year":"2016","unstructured":"Ginhoux, F. & Guilliams, M. Tissue-resident macrophage ontogeny and homeostasis. Immunity 44, 439\u2013449 (2016).","journal-title":"Immunity"},{"key":"2616_CR48","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1084\/jem.20131199","volume":"210","author":"M Guilliams","year":"2013","unstructured":"Guilliams, M. et al. Alveolar macrophages develop from fetal monocytes that differentiate into long-lived cells in the first week of life via GM-CSF. J. Exp. Med. 210, 1977\u20131992 (2013).","journal-title":"J. Exp. Med."},{"key":"2616_CR49","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.immuni.2022.08.010","volume":"55","author":"H Aegerter","year":"2022","unstructured":"Aegerter, H., Lambrecht, B. N. & Jakubzick, C. V. Biology of lung macrophages in health and disease. Immunity 55, 1564\u20131580 (2022).","journal-title":"Immunity"},{"key":"2616_CR50","doi-asserted-by":"publisher","unstructured":"Chakarov, S. et al. Two distinct interstitial macrophage populations coexist across tissues in specific subtissular niches. Science 363, eaau0964 https:\/\/doi.org\/10.1126\/science.aau0964 (2019).","DOI":"10.1126\/science.aau0964"},{"key":"2616_CR51","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/s41577-025-01186-x","volume":"25","author":"J Behmoaras","year":"2025","unstructured":"Behmoaras, J., Mulder, K., Ginhoux, F. & Petretto, E. The spatial and temporal activation of macrophages during fibrosis. Nat. Rev. Immunol. 25, 816\u2013830 (2025).","journal-title":"Nat. Rev. Immunol."},{"key":"2616_CR52","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adk5041","volume":"10","author":"A Farhat","year":"2025","unstructured":"Farhat, A. et al. An aging bone marrow exacerbates lung fibrosis by fueling profibrotic macrophage persistence. Sci. Immunol. 10, eadk5041 (2025).","journal-title":"Sci. Immunol."},{"key":"2616_CR53","doi-asserted-by":"publisher","unstructured":"Fabre, T. et al. Type 3 cytokines IL-17A and IL-22 drive TGF-\u03b2-dependent liver fibrosis. Sci. Immunol. 3, eaar7754 https:\/\/doi.org\/10.1126\/sciimmunol.aar7754 (2018).","DOI":"10.1126\/sciimmunol.aar7754"},{"key":"2616_CR54","doi-asserted-by":"crossref","unstructured":"Hart, K. M. et al. Type-2 immunity is protective in metabolic disease but exacerbates NAFLD collaboratively with TGF-\u03b2. Sci. Transl. Med. 9, eaal3694 (2017).","DOI":"10.1126\/scitranslmed.aal3694"},{"key":"2616_CR55","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1401739","volume":"370","author":"Idiopathic Pulmonary Fibrosis Clinical Research Network.","year":"2014","unstructured":"Idiopathic Pulmonary Fibrosis Clinical Research Network. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 370, 2093\u20132101 (2014).","journal-title":"N. Engl. J. Med."},{"key":"2616_CR56","first-page":"CD002880","volume":"2003","author":"L Richeldi","year":"2003","unstructured":"Richeldi, L., Davies, H. R., Ferrara, G. & Franco, F. Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database Syst. Rev. 2003, CD002880 (2003).","journal-title":"Cochrane Database Syst. Rev."},{"key":"2616_CR57","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1056\/NEJMoa1113354","volume":"366","author":"The Idiopathic Pulmonary Fibrosis Clinical Research Network.","year":"2012","unstructured":"The Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N. Engl. J. Med. 366, 1968\u20131977 (2012).","journal-title":"N. Engl. J. Med."},{"key":"2616_CR58","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.jaci.2014.11.001","volume":"135","author":"F Annunziato","year":"2015","unstructured":"Annunziato, F., Romagnani, C. & Romagnani, S. The 3 major types of innate and adaptive cell-mediated effector immunity. J. Allergy Clin. Immunol. 135, 626\u2013635 (2015).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2616_CR59","doi-asserted-by":"publisher","first-page":"26943","DOI":"10.1074\/jbc.M115.682138","volume":"290","author":"M Lacroix","year":"2015","unstructured":"Lacroix, M. et al. Novel Insights into interleukin 6 (IL-6) cis- and trans-signaling pathways by differentially manipulating the assembly of the IL-6 signaling complex. J. Biol. Chem. 290, 26943\u201326953 (2015).","journal-title":"J. Biol. Chem."},{"key":"2616_CR60","doi-asserted-by":"publisher","first-page":"L342","DOI":"10.1152\/ajplung.00016.2004","volume":"288","author":"H Kida","year":"2005","unstructured":"Kida, H. et al. Protective effect of IL-6 on alveolar epithelial cell death induced by hydrogen peroxide. Am. J. Physiol. Lung Cell. Mol. Physiol. 288, L342\u2013L349 (2005).","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"2616_CR61","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1111\/ajt.16417","volume":"21","author":"DS Wheeler","year":"2021","unstructured":"Wheeler, D. S. et al. Interleukin 6 trans-signaling is a critical driver of lung allograft fibrosis. Am. J. Transpl. 21, 2360\u20132371 (2021).","journal-title":"Am. J. Transpl."},{"key":"2616_CR62","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00281-016-0559-z","volume":"38","author":"LA Borthwick","year":"2016","unstructured":"Borthwick, L. A. The IL-1 cytokine family and its role in inflammation and fibrosis in the lung. Semin. Immunopathol. 38, 517\u2013534 (2016).","journal-title":"Semin. Immunopathol."},{"key":"2616_CR63","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/8539294","volume":"2017","author":"J Zheng","year":"2017","unstructured":"Zheng, J. et al. The expression of IL-6, TNF-\u03b1, and MCP-1 in respiratory viral infection in acute exacerbations of chronic obstructive pulmonary disease. J. Immunol. Res 2017, 8539294 (2017).","journal-title":"J. Immunol. Res"},{"key":"2616_CR64","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1590\/1414-431x20144402","volume":"48","author":"MR Bacci","year":"2015","unstructured":"Bacci, M. R. et al. IL-6 and TNF-\u03b1 serum levels are associated with early death in community-acquired pneumonia patients. Braz. J. Med Biol. Res 48, 427\u2013432 (2015).","journal-title":"Braz. J. Med Biol. Res"},{"key":"2616_CR65","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41584-023-01053-w","volume":"20","author":"E Landy","year":"2024","unstructured":"Landy, E., Carol, H., Ring, A. & Canna, S. Biological and clinical roles of IL-18 in inflammatory diseases. Nat. Rev. Rheumatol. 20, 33\u201347 (2024).","journal-title":"Nat. Rev. Rheumatol."},{"key":"2616_CR66","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/mi.2013.87","volume":"7","author":"MI Suwara","year":"2014","unstructured":"Suwara, M. I. et al. IL-1\u03b1 released from damaged epithelial cells is sufficient and essential to trigger inflammatory responses in human lung fibroblasts. Mucosal Immunol. 7, 684\u2013693 (2014).","journal-title":"Mucosal Immunol."},{"key":"2616_CR67","doi-asserted-by":"publisher","unstructured":"Leslie, J. et al. FPR-1 is an important regulator of neutrophil recruitment and a tissue-specific driver of pulmonary fibrosis. JCI Insight 5, e125937 https:\/\/doi.org\/10.1172\/jci.insight.125937 (2020).","DOI":"10.1172\/jci.insight.125937"},{"key":"2616_CR68","doi-asserted-by":"publisher","first-page":"3755","DOI":"10.4049\/jimmunol.1302470","volume":"193","author":"TT Le","year":"2014","unstructured":"Le, T. T. et al. Blockade of IL-6 Trans signaling attenuates pulmonary fibrosis. J. Immunol. 193, 3755\u20133768 (2014).","journal-title":"J. Immunol."},{"key":"2616_CR69","doi-asserted-by":"publisher","unstructured":"Yadav, P. et al. Myeloid-mesenchymal crosstalk drives ARG1-dependent profibrotic metabolism via ornithine in lung fibrosis. J. Clin. Invest. 135, e188734 https:\/\/doi.org\/10.1172\/JCI188734 (2025).","DOI":"10.1172\/JCI188734"},{"key":"2616_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2020.100140","volume":"1","author":"X Gao","year":"2020","unstructured":"Gao, X. et al. Osteopontin links myeloid activation and disease progression in systemic sclerosis. Cell Rep. Med 1, 100140 (2020).","journal-title":"Cell Rep. Med"},{"key":"2616_CR71","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1016\/S0012-3692(15)52722-0","volume":"128","author":"SA Papiris","year":"2005","unstructured":"Papiris, S. A. et al. Relationship of BAL and lung tissue CD4+ and CD8+ T lymphocytes, and their ratio in idiopathic pulmonary fibrosis. Chest 128, 2971\u20132977 (2005).","journal-title":"Chest"},{"key":"2616_CR72","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1172\/JCI5909","volume":"103","author":"Z Zhu","year":"1999","unstructured":"Zhu, Z. et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J. Clin. Invest. 103, 779\u2013788 (1999).","journal-title":"J. Clin. Invest."},{"key":"2616_CR73","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1084\/jem.20092121","volume":"207","author":"MS Wilson","year":"2010","unstructured":"Wilson, M. S. et al. Bleomycin and IL-1\u03b2-mediated pulmonary fibrosis is IL-17A dependent. J. Exp. Med. 207, 535\u2013552 (2010).","journal-title":"J. Exp. Med."},{"key":"2616_CR74","doi-asserted-by":"publisher","unstructured":"Gieseck, R. L. III, Wilson, M. S. & Wynn, T. A. Type 2 immunity in tissue repair and fibrosis. Nat. Rev. Immunol. 18, 62\u201376 https:\/\/doi.org\/10.1038\/nri.2017.90 (2017).","DOI":"10.1038\/nri.2017.90"},{"key":"2616_CR75","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jhep.2006.09.014","volume":"46","author":"H Weng","year":"2007","unstructured":"Weng, H., Mertens, P. R., Gressner, A. M. & Dooley, S. IFN\u03b3 abrogates profibrogenic TGF\u03b2 signaling in liver by targeting expression of inhibitory and receptor Smads. J. Hepatol. 46, 295\u2013303 (2007).","journal-title":"J. Hepatol."},{"key":"2616_CR76","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1002\/hep.21419","volume":"44","author":"WI Jeong","year":"2006","unstructured":"Jeong, W. I., Park, O., Radaeva, S. & Gao, B. STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity. Hepatology 44, 1441\u20131451 (2006).","journal-title":"Hepatology"},{"key":"2616_CR77","doi-asserted-by":"publisher","first-page":"L658","DOI":"10.1152\/ajplung.00006.2006","volume":"291","author":"J Xu","year":"2006","unstructured":"Xu, J., Mora, A. L., LaVoy, J., Brigham, K. L. & Rojas, M. Increased bleomycin-induced lung injury in mice deficient in the transcription factor T-bet. Am. J. Physiol. Lung Cell. Mol. Physiol. 291, L658\u2013L667 (2006).","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"2616_CR78","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S0140-6736(09)60551-1","volume":"374","author":"TE King Jr","year":"2009","unstructured":"King, T. E. Jr et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 374, 222\u2013228 (2009).","journal-title":"Lancet"},{"key":"2616_CR79","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa030511","volume":"350","author":"G Raghu","year":"2004","unstructured":"Raghu, G. et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 350, 125\u2013133 (2004).","journal-title":"N. Engl. J. Med."},{"key":"2616_CR80","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/path.4733","volume":"239","author":"TR Ramalingam","year":"2016","unstructured":"Ramalingam, T. R. et al. Enhanced protection from fibrosis and inflammation in the combined absence of IL-13 and IFN-\u03b3. J. Pathol. 239, 344\u2013354 (2016).","journal-title":"J. Pathol."},{"key":"2616_CR81","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abf2846","volume":"7","author":"DP Simmons","year":"2022","unstructured":"Simmons, D. P. et al. SLAMF7 engagement superactivates macrophages in acute and chronic inflammation. Sci. Immunol. 7, eabf2846 (2022).","journal-title":"Sci. Immunol."},{"key":"2616_CR82","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-021-00881-3","volume":"13","author":"F Zhang","year":"2021","unstructured":"Zhang, F. et al. IFN-\u03b3 and TNF-\u03b1 drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 lungs and inflammatory diseases with tissue inflammation. Genome Med. 13, 64 (2021).","journal-title":"Genome Med."},{"key":"2616_CR83","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1164\/rccm.200709-1446OC","volume":"178","author":"G Raghu","year":"2008","unstructured":"Raghu, G. et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 178, 948\u2013955 (2008).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2616_CR84","doi-asserted-by":"publisher","unstructured":"Franco, G. et al. Lack of efficacy of tocilizumab in acute exacerbation of pulmonary fibrosis. ERJ Open Res. 10, 00520-2024 https:\/\/doi.org\/10.1183\/23120541.00520-2024 (2024).","DOI":"10.1183\/23120541.00520-2024"},{"key":"2616_CR85","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1513\/AnnalsATS.202301-056OC","volume":"21","author":"M Ghazipura","year":"2024","unstructured":"Ghazipura, M. et al. Tocilizumab in patients with systemic sclerosis-associated interstitial lung disease: a systematic review and meta-analysis. Ann. Am. Thorac. Soc. 21, 328\u2013337 (2024).","journal-title":"Ann. Am. Thorac. Soc."},{"key":"2616_CR86","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.immuni.2021.12.014","volume":"55","author":"KM Cautivo","year":"2022","unstructured":"Cautivo, K. M. et al. Interferon gamma constrains type 2 lymphocyte niche boundaries during mixed inflammation. Immunity 55, 254\u2013271 (2022).","journal-title":"Immunity"},{"key":"2616_CR87","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/nri3831","volume":"15","author":"TA Wynn","year":"2015","unstructured":"Wynn, T. A. Type 2 cytokines: mechanisms and therapeutic strategies. Nat. Rev. Immunol. 15, 271\u2013282 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"2616_CR88","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.immuni.2016.06.009","volume":"45","author":"RL Gieseck III","year":"2016","unstructured":"Gieseck, R. L. III et al. Interleukin-13 activates distinct cellular pathways leading to ductular reaction, steatosis, and fibrosis. Immunity 45, 145\u2013158 (2016).","journal-title":"Immunity"},{"key":"2616_CR89","doi-asserted-by":"publisher","first-page":"4020","DOI":"10.4049\/jimmunol.173.6.4020","volume":"173","author":"M Kaviratne","year":"2004","unstructured":"Kaviratne, M. et al. IL-13 activates a mechanism of tissue fibrosis that is completely TGF-\u03b2 independent. J. Immunol. 173, 4020\u20134029 (2004).","journal-title":"J. Immunol."},{"key":"2616_CR90","doi-asserted-by":"publisher","first-page":"337ra365","DOI":"10.1126\/scitranslmed.aaf1938","volume":"8","author":"KM Vannella","year":"2016","unstructured":"Vannella, K. M. et al. Combinatorial targeting of TSLP, IL-25, and IL-33 in type 2 cytokine-driven inflammation and fibrosis. Sci. Transl. Med. 8, 337ra365 (2016).","journal-title":"Sci. Transl. Med."},{"key":"2616_CR91","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1165\/rcmb.2013-0093OC","volume":"49","author":"IG Luzina","year":"2013","unstructured":"Luzina, I. G. et al. Interleukin-33 potentiates bleomycin-induced lung injury. Am. J. Respir. Cell Mol. Biol. 49, 999\u20131008 (2013).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"2616_CR92","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.jaci.2014.05.011","volume":"134","author":"D Li","year":"2014","unstructured":"Li, D. et al. IL-33 promotes ST2-dependent lung fibrosis by the induction of alternatively activated macrophages and innate lymphoid cells in mice. J. Allergy Clin. Immunol. 134, 1422\u20131432 (2014).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2616_CR93","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.4049\/jimmunol.1300588","volume":"191","author":"A Datta","year":"2013","unstructured":"Datta, A. et al. Evidence for a functional thymic stromal lymphopoietin signaling axis in fibrotic lung disease. J. Immunol. 191, 4867\u20134879 (2013).","journal-title":"J. Immunol."},{"key":"2616_CR94","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1073\/pnas.1315854111","volume":"111","author":"E Hams","year":"2014","unstructured":"Hams, E. et al. IL-25 and type 2 innate lymphoid cells induce pulmonary fibrosis. Proc. Natl Acad. Sci. USA 111, 367\u2013372 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2616_CR95","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.immuni.2014.01.011","volume":"40","author":"TY Halim","year":"2014","unstructured":"Halim, T. Y. et al. Group 2 innate lymphoid cells are critical for the initiation of adaptive T helper 2 cell-mediated allergic lung inflammation. Immunity 40, 425\u2013435 (2014).","journal-title":"Immunity"},{"key":"2616_CR96","doi-asserted-by":"publisher","first-page":"3967","DOI":"10.1172\/JCI65570","volume":"123","author":"DE Byers","year":"2013","unstructured":"Byers, D. E. et al. Long-term IL-33-producing epithelial progenitor cells in chronic obstructive lung disease. J. Clin. Invest. 123, 3967\u20133982 (2013).","journal-title":"J. Clin. Invest."},{"key":"2616_CR97","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.immuni.2025.11.015","volume":"59","author":"S Verwaerde","year":"2026","unstructured":"Verwaerde, S. et al. Innate type 2 lymphocytes trigger an inflammatory switch in alveolar macrophages. Immunity 59, 60\u201378.e9 (2026).","journal-title":"Immunity"},{"key":"2616_CR98","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.jaci.2012.10.019","volume":"131","author":"L Roussel","year":"2013","unstructured":"Roussel, L., Farias, R. & Rousseau, S. IL-33 is expressed in epithelia from patients with cystic fibrosis and potentiates neutrophil recruitment. J. Allergy Clin. Immunol. 131, 913\u2013916 (2013).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2616_CR99","doi-asserted-by":"publisher","first-page":"403","DOI":"10.4049\/jimmunol.1200259","volume":"189","author":"IG Luzina","year":"2012","unstructured":"Luzina, I. G. et al. Full-length IL-33 promotes inflammation but not TH2 response in vivo in an ST2-independent fashion. J. Immunol. 189, 403\u2013410 (2012).","journal-title":"J. Immunol."},{"key":"2616_CR100","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1437767","volume":"15","author":"E Cocconcelli","year":"2024","unstructured":"Cocconcelli, E. et al. Tertiary lymphoid structures and B-cell infiltration are IPF features with functional consequences. Front. Immunol. 15, 1437767 (2024).","journal-title":"Front. Immunol."},{"key":"2616_CR101","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s12931-019-1195-7","volume":"20","author":"P Heukels","year":"2019","unstructured":"Heukels, P. et al. Enhanced Bruton\u2019s tyrosine kinase in B-cells and autoreactive IgA in patients with idiopathic pulmonary fibrosis. Respir. Res. 20, 232 (2019).","journal-title":"Respir. Res."},{"key":"2616_CR102","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/1845128","volume":"2019","author":"R Mills","year":"2019","unstructured":"Mills, R. et al. Intrapulmonary Autoantibodies to HSP72 Are Associated with Improved Outcomes in IPF. J. Immunol. Res 2019, 1845128 (2019).","journal-title":"J. Immunol. Res"},{"key":"2616_CR103","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1002\/art.23995","volume":"58","author":"K Komura","year":"2008","unstructured":"Komura, K. et al. CD19 regulates the development of bleomycin-induced pulmonary fibrosis in a mouse model. Arthritis Rheum. 58, 3574\u20133584 (2008).","journal-title":"Arthritis Rheum."},{"key":"2616_CR104","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1513\/AnnalsATS.202301-055OC","volume":"21","author":"M Macrea","year":"2024","unstructured":"Macrea, M. et al. Rituximab in patients with systemic sclerosis-associated interstitial lung disease: a systematic review and meta-analysis. Ann. Am. Thorac. Soc. 21, 317\u2013327 (2024).","journal-title":"Ann. Am. Thorac. Soc."},{"key":"2616_CR105","doi-asserted-by":"publisher","first-page":"L796","DOI":"10.1152\/ajplung.00184.2017","volume":"313","author":"B Singh","year":"2017","unstructured":"Singh, B., Kasam, R. K., Sontake, V., Wynn, T. A. & Madala, S. K. Repetitive intradermal bleomycin injections evoke T-helper cell 2 cytokine-driven pulmonary fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 313, L796\u2013L806 (2017).","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"2616_CR106","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1165\/rcmb.2013-0342OC","volume":"50","author":"LA Murray","year":"2014","unstructured":"Murray, L. A. et al. Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model. Am. J. Respir. Cell Mol. Biol. 50, 985\u2013994 (2014).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"2616_CR107","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/nm734","volume":"8","author":"DA Kuperman","year":"2002","unstructured":"Kuperman, D. A. et al. Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma. Nat. Med. 8, 885\u2013889 (2002).","journal-title":"Nat. Med."},{"key":"2616_CR108","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1084\/jem.20020009","volume":"195","author":"J Mattes","year":"2002","unstructured":"Mattes, J. et al. Intrinsic defect in T cell production of interleukin (IL)-13 in the absence of both IL-5 and eotaxin precludes the development of eosinophilia and airways hyperreactivity in experimental asthma. J. Exp. Med. 195, 1433\u20131444 (2002).","journal-title":"J. Exp. Med."},{"key":"2616_CR109","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","volume":"378","author":"M Castro","year":"2018","unstructured":"Castro, M. et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N. Engl. J. Med. 378, 2486\u20132496 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2616_CR110","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2303951","volume":"389","author":"SP Bhatt","year":"2023","unstructured":"Bhatt, S. P. et al. Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts. N. Engl. J. Med. 389, 205\u2013214 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2616_CR111","doi-asserted-by":"publisher","first-page":"e004407","DOI":"10.1136\/bmjopen-2013-004407","volume":"4","author":"J Tanaka","year":"2014","unstructured":"Tanaka, J. et al. An observational study of giant cell interstitial pneumonia and lung fibrosis in hard metal lung disease. BMJ Open 4, e004407 (2014).","journal-title":"BMJ Open"},{"key":"2616_CR112","doi-asserted-by":"publisher","first-page":"240ra276","DOI":"10.1126\/scitranslmed.3007096","volume":"6","author":"Y Zhou","year":"2014","unstructured":"Zhou, Y. et al. Chitinase 3-like 1 suppresses injury and promotes fibroproliferative responses in Mammalian lung fibrosis. Sci. Transl. Med. 6, 240ra276 (2014).","journal-title":"Sci. Transl. Med."},{"key":"2616_CR113","doi-asserted-by":"publisher","unstructured":"Lodyga, M. et al. Cadherin-11-mediated adhesion of macrophages to myofibroblasts establishes a profibrotic niche of active TGF-\u03b2. Sci. Signal 12, eaao3469 https:\/\/doi.org\/10.1126\/scisignal.aao3469 (2019).","DOI":"10.1126\/scisignal.aao3469"},{"key":"2616_CR114","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1183\/09031936.00068712","volume":"43","author":"R Firszt","year":"2014","unstructured":"Firszt, R. et al. Interleukin-13 induces collagen type-1 expression through matrix metalloproteinase-2 and transforming growth factor-\u03b21 in airway fibroblasts in asthma. Eur. Respir. J. 43, 464\u2013473 (2014).","journal-title":"Eur. Respir. J."},{"key":"2616_CR115","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/bjd.19574","volume":"184","author":"A Wollenberg","year":"2021","unstructured":"Wollenberg, A. et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br. J. Dermatol 184, 437\u2013449 (2021).","journal-title":"Br. J. Dermatol"},{"key":"2616_CR116","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aea6805","volume":"12","author":"J Sbierski-Kind","year":"2026","unstructured":"Sbierski-Kind, J. et al. Type 2 lymphocytes restrict type 3 lymphocytes during liver fibrosis and colocalize in fibroblast niches. Sci. Adv. 12, eaea6805 (2026).","journal-title":"Sci. Adv."},{"key":"2616_CR117","doi-asserted-by":"publisher","first-page":"301ra129","DOI":"10.1126\/scitranslmed.aab3142","volume":"7","author":"DF Choy","year":"2015","unstructured":"Choy, D. F. et al. TH2 and TH17 inflammatory pathways are reciprocally regulated in asthma. Sci. Transl. Med. 7, 301ra129 (2015).","journal-title":"Sci. Transl. Med."},{"key":"2616_CR118","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2018.07.028","volume":"124","author":"MF Molina","year":"2019","unstructured":"Molina, M. F., Abdelnabi, M. N., Fabre, T. & Shoukry, N. H. Type 3 cytokines in liver fibrosis and liver cancer. Cytokine 124, 154497 (2019).","journal-title":"Cytokine"},{"key":"2616_CR119","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59218-y","volume":"16","author":"R Al Sayegh","year":"2025","unstructured":"Al Sayegh, R. et al. Defective autophagy in CD4 T cells drives liver fibrosis via type 3 inflammation. Nat. Commun. 16, 3860 (2025).","journal-title":"Nat. Commun."},{"key":"2616_CR120","doi-asserted-by":"publisher","first-page":"F385","DOI":"10.1152\/ajprenal.00462.2016","volume":"312","author":"P Mehrotra","year":"2017","unstructured":"Mehrotra, P. et al. IL-17 mediates neutrophil infiltration and renal fibrosis following recovery from ischemia reperfusion: compensatory role of natural killer cells in athymic rats. Am. J. Physiol. Ren. Physiol. 312, F385\u2013F397 (2017).","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"2616_CR121","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1053\/j.gastro.2012.05.049","volume":"143","author":"F Meng","year":"2012","unstructured":"Meng, F. et al. Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology 143, 765\u2013776 (2012).","journal-title":"Gastroenterology"},{"key":"2616_CR122","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.resinv.2023.05.005","volume":"61","author":"S Senoo","year":"2023","unstructured":"Senoo, S. et al. Pulmonary fibrosis and type-17 immunity. Respir. Investig. 61, 553\u2013562 (2023).","journal-title":"Respir. Investig."},{"key":"2616_CR123","doi-asserted-by":"publisher","first-page":"L925","DOI":"10.1152\/ajplung.00582.2020","volume":"321","author":"S Senoo","year":"2021","unstructured":"Senoo, S. et al. Essential role of IL-23 in the development of acute exacerbation of pulmonary fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 321, L925\u2013L940 (2021).","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"2616_CR124","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/path.4430","volume":"235","author":"X Peng","year":"2015","unstructured":"Peng, X. et al. IL-17A produced by both gammadelta T and TH17 cells promotes renal fibrosis via RANTES-mediated leukocyte infiltration after renal obstruction. J. Pathol. 235, 79\u201389 (2015).","journal-title":"J. Pathol."},{"key":"2616_CR125","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.4049\/jimmunol.1203013","volume":"191","author":"Z Tan","year":"2013","unstructured":"Tan, Z. et al. IL-17A plays a critical role in the pathogenesis of liver fibrosis through hepatic stellate cell activation. J. Immunol. 191, 1835\u20131844 (2013).","journal-title":"J. Immunol."},{"key":"2616_CR126","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.jaci.2009.03.033","volume":"123","author":"C Nembrini","year":"2009","unstructured":"Nembrini, C., Marsland, B. J. & Kopf, M. IL-17-producing T cells in lung immunity and inflammation. J. Allergy Clin. Immunol. 123, 986\u2013994 (2009).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2616_CR127","first-page":"14","volume":"34","author":"L Lei","year":"2016","unstructured":"Lei, L. et al. TH17 cells and IL-17 promote the skin and lung inflammation and fibrosis process in a bleomycin-induced murine model of systemic sclerosis. Clin. Exp. Rheumatol. 34, 14\u201322 (2016).","journal-title":"Clin. Exp. Rheumatol."},{"key":"2616_CR128","doi-asserted-by":"publisher","unstructured":"Celada, L. J. et al. PD-1 up-regulation on CD4+ T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-beta1 production. Sci. Transl Med. 10, eaar8356 https:\/\/doi.org\/10.1126\/scitranslmed.aar8356 (2018).","DOI":"10.1126\/scitranslmed.aar8356"},{"key":"2616_CR129","doi-asserted-by":"publisher","unstructured":"Sommerfeld, S. D. et al. Interleukin-36\u03b3-producing macrophages drive IL-17-mediated fibrosis. Sci. Immunol. 4, eaax4783 https:\/\/doi.org\/10.1126\/sciimmunol.aax4783 (2019).","DOI":"10.1126\/sciimmunol.aax4783"},{"key":"2616_CR130","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.jhep.2019.12.016","volume":"72","author":"HY Ma","year":"2020","unstructured":"Ma, H. Y. et al. IL-17 signaling in steatotic hepatocytes and macrophages promotes hepatocellular carcinoma in alcohol-related liver disease. J. Hepatol. 72, 946\u2013959 (2020).","journal-title":"J. Hepatol."},{"key":"2616_CR131","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1046\/j.1365-2249.2002.01782.x","volume":"127","author":"A Kehlen","year":"2002","unstructured":"Kehlen, A., Thiele, K., Riemann, D. & Langner, J. Expression, modulation and signalling of IL-17 receptor in fibroblast-like synoviocytes of patients with rheumatoid arthritis. Clin. Exp. Immunol. 127, 539\u2013546 (2002).","journal-title":"Clin. Exp. Immunol."},{"key":"2616_CR132","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.4049\/jimmunol.1400861","volume":"193","author":"T Fabre","year":"2014","unstructured":"Fabre, T., Kared, H., Friedman, S. L. & Shoukry, N. H. IL-17A enhances the expression of profibrotic genes through upregulation of the TGF-beta receptor on hepatic stellate cells in a JNK-dependent manner. J. Immunol. 193, 3925\u20133933 (2014).","journal-title":"J. Immunol."},{"key":"2616_CR133","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1038\/nm.3282","volume":"19","author":"NC Henderson","year":"2013","unstructured":"Henderson, N. C. et al. Targeting of alphav integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat. Med. 19, 1617\u20131624 (2013).","journal-title":"Nat. Med."},{"key":"2616_CR134","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/path.5215","volume":"248","author":"JC Sciurba","year":"2019","unstructured":"Sciurba, J. C. et al. Fibroblast-specific integrin-alpha V differentially regulates type 17 and type 2 driven inflammation and fibrosis. J. Pathol. 248, 16\u201329 (2019).","journal-title":"J. Pathol."},{"key":"2616_CR135","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.biocel.2007.11.026","volume":"40","author":"G Jenkins","year":"2008","unstructured":"Jenkins, G. The role of proteases in transforming growth factor-beta activation. Int. J. Biochem. Cell Biol. 40, 1068\u20131078 (2008).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"2616_CR136","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/s41586-019-1631-3","volume":"575","author":"P Ramachandran","year":"2019","unstructured":"Ramachandran, P. et al. Resolving the fibrotic niche of human liver cirrhosis at single-cell level. Nature 575, 512\u2013518 (2019).","journal-title":"Nature"},{"key":"2616_CR137","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.509","volume":"11","author":"P Gu","year":"2021","unstructured":"Gu, P. et al. Protective function of interleukin-22 in pulmonary fibrosis. Clin. Transl. Med 11, e509 (2021).","journal-title":"Clin. Transl. Med"},{"key":"2616_CR138","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S0083-6729(06)74004-3","volume":"74","author":"RAP Nagem","year":"2006","unstructured":"Nagem, R. A. P., Ferreira Junior, J. R., Dumoutier, L., Renauld, J.-C. & Polikarpov, I. Interleukin-22 and its crystal structure. Vitam. Horm. 74, 77\u2013103 (2006).","journal-title":"Vitam. Horm."},{"key":"2616_CR139","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1084\/jem.20092054","volume":"207","author":"GF Sonnenberg","year":"2010","unstructured":"Sonnenberg, G. F. et al. Pathological versus protective functions of IL-22 in airway inflammation are regulated by IL-17A. J. Exp. Med. 207, 1293\u20131305 (2010).","journal-title":"J. Exp. Med."},{"key":"2616_CR140","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/B978-0-12-381300-8.00001-0","volume":"107","author":"GF Sonnenberg","year":"2010","unstructured":"Sonnenberg, G. F., Fouser, L. A. & Artis, D. Functional biology of the IL-22-IL-22R pathway in regulating immunity and inflammation at barrier surfaces. Adv. Immunol. 107, 1\u201329 (2010).","journal-title":"Adv. Immunol."},{"key":"2616_CR141","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1084\/jem.20100061","volume":"207","author":"PL Simonian","year":"2010","unstructured":"Simonian, P. L. et al. gammadelta T cells protect against lung fibrosis via IL-22. J. Exp. Med. 207, 2239\u20132253 (2010).","journal-title":"J. Exp. Med."},{"key":"2616_CR142","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.4049\/jimmunol.1700587","volume":"199","author":"D Kleinschmidt","year":"2017","unstructured":"Kleinschmidt, D. et al. A protective function of IL-22BP in ISchemia Reperfusion and Acetaminophen-induced Liver Injury. J. Immunol. 199, 4078\u20134090 (2017).","journal-title":"J. Immunol."},{"key":"2616_CR143","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.clim.2015.03.003","volume":"158","author":"LY Wu","year":"2015","unstructured":"Wu, L. Y. et al. Up-regulation of interleukin-22 mediates liver fibrosis via activating hepatic stellate cells in patients with hepatitis C. Clin. Immunol. 158, 77\u201387 (2015).","journal-title":"Clin. Immunol."},{"key":"2616_CR144","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1053\/j.gastro.2016.09.064","volume":"151","author":"J Xue","year":"2016","unstructured":"Xue, J. et al. Aryl hydrocarbon receptor ligands in cigarette smoke induce production of interleukin-22 to promote pancreatic fibrosis in models of chronic pancreatitis. Gastroenterology 151, 1206\u20131217 (2016).","journal-title":"Gastroenterology"},{"key":"2616_CR145","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/s41385-019-0146-4","volume":"12","author":"R Mathur","year":"2019","unstructured":"Mathur, R. et al. Induction of autophagy in Cx3cr1+ mononuclear cells limits IL-23\/IL-22 axis-mediated intestinal fibrosis. Mucosal Immunol. 12, 612\u2013623 (2019).","journal-title":"Mucosal Immunol."},{"key":"2616_CR146","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.jcmgh.2022.08.001","volume":"14","author":"MN Abdelnabi","year":"2022","unstructured":"Abdelnabi, M. N. et al. Sex-dependent hepatoprotective role of IL-22 receptor signaling in non-alcoholic fatty liver disease-related fibrosis. Cell Mol. Gastroenterol. Hepatol. 14, 1269\u20131294 (2022).","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"2616_CR147","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.ajpath.2023.11.011","volume":"194","author":"Z Zhang","year":"2024","unstructured":"Zhang, Z. et al. IL-22 binding protein controls IL-22-driven bleomycin-induced lung injury. Am. J. Pathol. 194, 338\u2013352 (2024).","journal-title":"Am. J. Pathol."},{"key":"2616_CR148","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.jaad.2023.02.061","volume":"89","author":"T Fukasawa","year":"2023","unstructured":"Fukasawa, T. et al. Interleukin-17 pathway inhibition with brodalumab in early systemic sclerosis: Analysis of a single-arm, open-label, phase 1 trial. J. Am. Acad. Dermatol 89, 366\u2013369 (2023).","journal-title":"J. Am. Acad. Dermatol"},{"key":"2616_CR149","doi-asserted-by":"publisher","unstructured":"Bohdziewicz, A. et al. Future Treatment Options in Systemic Sclerosis-Potential Targets and Ongoing Clinical Trials. J. Clin. Med. 11, 1310 https:\/\/doi.org\/10.3390\/jcm11051310 (2022).","DOI":"10.3390\/jcm11051310"},{"key":"2616_CR150","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1056\/NEJMoa2414108","volume":"392","author":"L Richeldi","year":"2025","unstructured":"Richeldi, L. et al. Nerandomilast in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 392, 2193\u20132202 (2025).","journal-title":"N. Engl. J. Med."},{"key":"2616_CR151","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1038\/d41586-026-00109-7","volume":"649","author":"T Vernimmen","year":"2026","unstructured":"Vernimmen, T. Treatments for idiopathic pulmonary fibrosis are on the horizon. Nature 649, S13\u2013S15 (2026).","journal-title":"Nature"},{"key":"2616_CR152","doi-asserted-by":"publisher","first-page":"997","DOI":"10.2147\/DDDT.S288369","volume":"15","author":"K Ubieta","year":"2021","unstructured":"Ubieta, K., Thomas, M. J. & Wollin, L. The effect of nintedanib on T-cell activation, subsets and functions. Drug Des. Devel. Ther. 15, 997\u20131011 (2021).","journal-title":"Drug Des. Devel. Ther."},{"key":"2616_CR153","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1165\/rcmb.2005-0452OC","volume":"35","author":"A Hirano","year":"2006","unstructured":"Hirano, A. et al. Pirfenidone modulates airway responsiveness, inflammation, and remodeling after repeated challenge. Am. J. Respir. Cell Mol. Biol. 35, 366\u2013377 (2006).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"2616_CR154","doi-asserted-by":"publisher","first-page":"4766","DOI":"10.1111\/bph.17303","volume":"181","author":"D Reininger","year":"2024","unstructured":"Reininger, D. et al. PDE4B inhibition by nerandomilast: effects on lung fibrosis and transcriptome in fibrotic rats and on biomarkers in human lung epithelial cells. Br. J. Pharmacol. 181, 4766\u20134781 (2024).","journal-title":"Br. J. Pharmacol."},{"key":"2616_CR155","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1007\/s10753-024-02153-9","volume":"48","author":"Y Liu","year":"2025","unstructured":"Liu, Y. et al. Nerandomilast improves bleomycin-induced systemic sclerosis-associated interstitial lung disease in mice by regulating the TGF-beta1 pathway. Inflammation 48, 1760\u20131774 (2025).","journal-title":"Inflammation"},{"key":"2616_CR156","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41586-023-06797-9","volume":"625","author":"NM LaMarche","year":"2024","unstructured":"LaMarche, N. M. et al. An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis. Nature 625, 166\u2013174 (2024).","journal-title":"Nature"},{"key":"2616_CR157","doi-asserted-by":"publisher","first-page":"7492","DOI":"10.1016\/j.cell.2024.10.006","volume":"187","author":"G Mollaoglu","year":"2024","unstructured":"Mollaoglu, G. et al. Ovarian cancer-derived IL-4 promotes immunotherapy resistance. Cell 187, 7492\u20137510 (2024).","journal-title":"Cell"},{"key":"2616_CR158","doi-asserted-by":"publisher","DOI":"10.1038\/srep41770","volume":"7","author":"M Schuliga","year":"2017","unstructured":"Schuliga, M. et al. The fibrogenic actions of lung fibroblast-derived urokinase: a potential drug target in IPF. Sci. Rep. 7, 41770 (2017).","journal-title":"Sci. Rep."},{"key":"2616_CR159","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.905727","volume":"13","author":"CY Lo","year":"2022","unstructured":"Lo, C. Y. et al. Increased interleukin-17 and glucocorticoid receptor-beta expression in interstitial lung diseases and corticosteroid insensitivity. Front. Immunol. 13, 905727 (2022).","journal-title":"Front. Immunol."},{"key":"2616_CR160","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3346\/jkms.2009.24.4.614","volume":"24","author":"SW Park","year":"2009","unstructured":"Park, S. W. et al. Interleukin-13 and its receptors in idiopathic interstitial pneumonia: clinical implications for lung function. J. Korean Med. Sci. 24, 614\u2013620 (2009).","journal-title":"J. Korean Med. Sci."},{"key":"2616_CR161","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","volume":"198","author":"G Raghu","year":"2018","unstructured":"Raghu, G. et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am. J. Respir. Crit. Care Med. 198, e44\u2013e68 (2018).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2616_CR162","doi-asserted-by":"publisher","first-page":"91","DOI":"10.21037\/atm.2017.02.07","volume":"5","author":"KM Hart","year":"2017","unstructured":"Hart, K. M., Choy, D. F., Bradding, P., Wynn, T. A. & Arron, J. R. Accurately measuring and modeling TH2 and TH17 endotypes in severe asthma. Ann. Transl. Med. 5, 91 (2017).","journal-title":"Ann. Transl. Med."},{"key":"2616_CR163","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.cyto.2017.08.019","volume":"102","author":"SA Papiris","year":"2018","unstructured":"Papiris, S. A. et al. High levels of IL-6 and IL-8 characterize early-on idiopathic pulmonary fibrosis acute exacerbations. Cytokine 102, 168\u2013172 (2018).","journal-title":"Cytokine"},{"key":"2616_CR164","doi-asserted-by":"publisher","first-page":"e0241719","DOI":"10.1371\/journal.pone.0241719","volume":"15","author":"M Kameda","year":"2020","unstructured":"Kameda, M. et al. CXCL9, CXCL10, and CXCL11; biomarkers of pulmonary inflammation associated with autoimmunity in patients with collagen vascular diseases-associated interstitial lung disease and interstitial pneumonia with autoimmune features. PLoS ONE 15, e0241719 (2020).","journal-title":"PLoS ONE"},{"key":"2616_CR165","doi-asserted-by":"publisher","unstructured":"Raghu, G. et al. SAR156597 in idiopathic pulmonary fibrosis: a phase 2 placebo-controlled study (DRI11772). Eur. Respir. J. 52, 1801130 https:\/\/doi.org\/10.1183\/13993003.01130-2018 (2018).","DOI":"10.1183\/13993003.01130-2018"},{"key":"2616_CR166","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.resinv.2014.12.003","volume":"53","author":"M Tajiri","year":"2015","unstructured":"Tajiri, M. et al. Serum level of periostin can predict long-term outcome of idiopathic pulmonary fibrosis. Respir. Investig. 53, 73\u201381 (2015).","journal-title":"Respir. Investig."},{"key":"2616_CR167","doi-asserted-by":"publisher","first-page":"L1046","DOI":"10.1152\/ajplung.00139.2012","volume":"303","author":"PK Naik","year":"2012","unstructured":"Naik, P. K. et al. Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 303, L1046\u2013L1056 (2012).","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"2616_CR168","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2026.108640","volume":"252","author":"M David","year":"2026","unstructured":"David, M. et al. Blood eosinophilia as a predictor of acute exacerbation in fibrotic interstitial lung diseases. Respir. Med. 252, 108640 (2026).","journal-title":"Respir. Med."},{"key":"2616_CR169","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.810338","volume":"13","author":"Y Li","year":"2022","unstructured":"Li, Y. et al. S100A12 as biomarker of disease severity and prognosis in patients with idiopathic pulmonary fibrosis. Front. Immunol. 13, 810338 (2022).","journal-title":"Front. Immunol."},{"key":"2616_CR170","first-page":"17182","volume":"42","author":"J Pan","year":"2025","unstructured":"Pan, J., Li, G., Pu, Y., Li, P. & Zhou, Y. Unveiling CCL2 and CXCL1: key biomarkers and therapeutic targets in idiopathic pulmonary fibrosis. Sarcoidosis Vasc. Diffus. Lung Dis. 42, 17182 (2025).","journal-title":"Sarcoidosis Vasc. Diffus. Lung Dis."},{"key":"2616_CR171","doi-asserted-by":"publisher","first-page":"e251","DOI":"10.1371\/journal.pmed.0020251","volume":"2","author":"A Pardo","year":"2005","unstructured":"Pardo, A. et al. Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis. PLoS Med. 2, e251 (2005).","journal-title":"PLoS Med."},{"key":"2616_CR172","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/resp.14894","volume":"30","author":"RM Li","year":"2025","unstructured":"Li, R. M. et al. Pre-treatment MMP7 predicts progressive idiopathic pulmonary fibrosis in antifibrotic treated patients. Respirology 30, 504\u2013514 (2025).","journal-title":"Respirology"},{"key":"2616_CR173","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1164\/rccm.200808-1201OC","volume":"179","author":"A Prasse","year":"2009","unstructured":"Prasse, A. et al. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 179, 717\u2013723 (2009).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2616_CR174","doi-asserted-by":"publisher","unstructured":"Achaiah, A. et al. Neutrophil levels correlate with quantitative extent and progression of fibrosis in IPF: results of a single-centre cohort study. BMJ Open Respir. Res. 10, e001801 https:\/\/doi.org\/10.1136\/bmjresp-2023-001801 (2023).","DOI":"10.1136\/bmjresp-2023-001801"}],"container-title":["Nature Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41590-026-02616-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41590-026-02616-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41590-026-02616-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T16:02:52Z","timestamp":1787673772000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41590-026-02616-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":174,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2616"],"URL":"https:\/\/doi.org\/10.1038\/s41590-026-02616-1","relation":{},"ISSN":["1529-2908","1529-2916"],"issn-type":[{"value":"1529-2908","type":"print"},{"value":"1529-2916","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"assertion":[{"value":"24 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All three authors are employed by Pfizer and declare no relevant funding. T.F., T.A.W. and K.M.H. are employees of Pfizer Inc.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}